BioLineRx (BLRX) Net Cash Flow Growth (3y) (2016 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 89.97% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -13.44% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 33.37% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -29.82% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 32.17% |
| 10 | BioLineRx | 9.32 Bn | 9.30 Bn | 154,000.00 | -24.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -24.73% |
| Sep 30, 2025 | 39.65% |
| Jun 30, 2025 | -40.04% |
| Mar 31, 2025 | 3.81% |
| Dec 31, 2024 | 45.50% |
| Sep 30, 2024 | 36.55% |
| Jun 30, 2024 | 45.64% |
| Mar 31, 2024 | 69.72% |
| Dec 31, 2023 | -33.22% |
| Sep 30, 2023 | -62.02% |
| Jun 30, 2023 | 46.66% |
| Mar 31, 2023 | -107.19% |
| Dec 31, 2022 | -107.94% |
| Sep 30, 2022 | -106.64% |
| Jun 30, 2022 | 76.85% |
| Mar 31, 2022 | -51.95% |
| Dec 31, 2021 | -0.69% |
| Sep 30, 2021 | -64.17% |
| Jun 30, 2021 | 37.32% |
| Mar 31, 2021 | -30.41% |
| Dec 31, 2020 | 98.44% |
| Sep 30, 2020 | 72.88% |
| Jun 30, 2020 | -55.51% |
| Mar 31, 2020 | 23.83% |
| Dec 31, 2019 | 30.64% |
| Sep 30, 2019 | -41.90% |
| Jun 30, 2019 | 39.85% |
| Mar 31, 2019 | 44.63% |
| Dec 31, 2018 | -144.07% |
| Sep 30, 2018 | 42.36% |
| Jun 30, 2018 | -53.88% |
| Mar 31, 2018 | 4.86% |
| Dec 31, 2017 | -52.06% |
| Sep 30, 2017 | 54.34% |
| Jun 30, 2017 | 101.07% |
| Mar 31, 2017 | -61.61% |
| Dec 31, 2016 | 21.34% |
| Sep 30, 2016 | 27.28% |
| Jun 30, 2016 | -39.42% |
| Mar 31, 2016 | 44.98% |